A Randomized, Open Label, Multicenter Phase 2 Study, to Evaluate the Efficacy of Sorafenib in Patients With Advanced Renal Cell Carcinoma (RCC) After a Radical Resection of the Metastases.
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms RESORT
- 05 Jun 2018 Interim results at median follow-up of 21 months (n=68) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 10 Jun 2017 Biomarkers information updated
- 20 Mar 2017 Planned End Date changed from 1 Sep 2016 to 1 Sep 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History